有静脉血栓栓塞病史患者行全髋与全膝关节置换术后阿司匹林对比依诺肝素的安全性与疗效
该研究利用全支付方理赔数据库,纳入2015年1月至2021年12月择期初次全髋关节置换术(THA)和全膝关节置换术(TKA)且有静脉血栓栓塞(VTE)病史的患者,按1:1匹配阿司匹林(ASA)与依诺肝素组。多变量分析显示,ASA组与依诺肝素组肺栓塞和深静脉血栓(DVT)风险相似,TKA患者ASA组DVT风险较低,THA患者ASA组卒中风险降低,TKA患者ASA组急性失血性贫血风险较低。结论认为高危患者使用ASA未增加不良结局风险。
要点
- 有VTE病史的THA和TKA患者中,ASA组与依诺肝素组肺栓塞和DVT风险相似。
- TKA患者ASA组DVT风险低于依诺肝素组(aOR 0.57,95%CI 0.33-0.96)。
- THA患者ASA组卒中风险降低(aOR 0.03,95%CI 0.00-0.73),TKA患者ASA组急性失血性贫血风险较低(aOR 0.77,95%CI 0.66-0.88)。
核心结论
- 有VTE病史的高危患者接受ASA后肺栓塞和DVT风险与依诺肝素相似,但出血相关和内科并发症风险降低。
- 高危患者使用ASA未与不良结局风险增加相关。
研究设计与样本
- 基于全支付方理赔数据库的查询研究,纳入2015年1月至2021年12月初次择期THA和TKA患者。
- 有VTE病史的患者按接受ASA或依诺肝素分为两组,以1:1比例匹配,1,429例THA和2,864例TKA高危ASA患者与高危依诺肝素患者按年龄、性别、种族和相关合并症匹配。
- 采用多变量回归分析控制潜在混杂因素。
主要发现
- 多变量分析后,ASA组与依诺肝素组肺栓塞风险相似(THA:aOR 0.85,95%CI 0.26-2.76;TKA:aOR 0.71,95%CI 0.38-1.32)。
- ASA组与依诺肝素组DVT风险在THA中相似(aOR 1.12,95%CI 0.53-2.36),TKA患者ASA组DVT风险低于依诺肝素组(aOR 0.57,95%CI 0.33-0.96)。
- THA患者ASA组卒中风险降低(aOR 0.03,95%CI 0.00-0.73)。
- TKA患者ASA组急性失血性贫血风险较低(aOR 0.77,95%CI 0.66-0.88)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the broad utilization of aspirin (ASA) as a venous thromboembolism (VTE) chemoprophylactic agent following total knee arthroplasty (TKA) and total hip arthroplasty (THA), few studies have evaluated its safety and efficacy in patients who had a history of VTE. This study sought to evaluate the safety and efficacy of ASA relative to enoxaparin in high-risk total joint arthroplasty patients. METHODS: An all-payer claims database was queried for primary, elective THA, and TKA patients from January 2015 to December 2021. Patients who had a history of VTE were divided based on receipt of either ASA or enoxaparin as VTE prophylaxis. In a 1:1 ratio, 1,429 THA and 2,864 TKA high-risk ASA patients were matched to high-risk enoxaparin patients on age, sex, race, and presence of pertinent comorbidities. Multivariable regression analyses accounted for potential confounders. RESULTS: After multivariable analyses, similar risk of pulmonary embolism (THA: adjusted odds ratio [aOR]: 0.85, 95% confidence interval [CI]: 0.26 to 2.76; TKA: aOR: 0.71, 95% CI: 0.38 to 1.32) and deep vein thrombosis (DVT) (THA: aOR: 1.12, 95% CI: 0.53 to 2.36) was observed in the ASA cohorts relative to the enoxaparin cohorts. TKA patients in the ASA cohort had a lower risk of DVT than those in the enoxaparin cohort (aOR: 0.57, 95% CI: 0.33 to 0.96). THA ASA patients demonstrated a reduced risk of stroke (aOR: 0.03, 95% CI: 0.00 to 0.73), while TKA ASA patients had a lower risk of acute blood loss anemia (aOR: 0.77, 95% CI: 0.66 to 0.88). CONCLUSIONS: High-risk patients who received ASA demonstrated similar risk of pulmonary embolism and DVT, but decreased risk of bleeding-related and medical complications compared to patients who received enoxaparin. The utilization of ASA in high-risk patients was not associated with an increased risk of adverse outcomes.
引用
- Liu KC, Griffith KM, Richardson MK, et al. Safety and Efficacy of Aspirin Compared to Enoxaparin Following Total Hip and Total Knee Arthroplasty Among Patients Who Have a History of Venous Thromboembolic Disease. J Arthroplasty. 2024. PMID: 39561910. doi:10.1016/j.arth.2024.11.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。